antiretroviral therapy
Transitions From Daily Dovato to Long-Acting Cabenuva Wanted by Patients With HIV
Many people with HIV want to transition from viral suppression with daily oral Dovato to long-acting injectable ...
JULY 23, 2025
Very Early ART May Be 1 Key to Remission
Starting HIV antiretroviral therapy shortly after diagnosis could promote long-term control if a person ...
JANUARY 26, 2024
Daily Statin Reduces CV Events by 35% Among Adults With HIV
The risk for CVD in people living with HIV can be 50% to 100% greater than those without HIV.
AUGUST 8, 2023
Sometimes Even ‘Detectable’ Can Mean Untransmissible
People living with HIV who maintain low—but still detectible—levels of the virus but adhere to their ...
JULY 26, 2023
New START Data Reinforces Benefits of Early ART
New START data confirm that starting antiretroviral treatment (ART) early in the course of HIV infection when the ...
DECEMBER 2, 2022
Current Options for Highly Treatment-Experienced People With HIV
The treatment of HIV has dramatically advanced over the past 40 years. Clear data show a decreased occurrence of ...
JUNE 22, 2022
‘Things Can Go Downhill’ From Med Errors for Patients With HIV
Errors related to antiretroviral therapy among hospitalized patients with HIV can have a significant long-term ...
MAY 20, 2022
Clinical and Financial Compliance Tips for HIV
With HIV at or near the top of the specialty drug spending trend for both Medicaid and commercial payors, ...
FEBRUARY 23, 2021
How Close Are We to Curing HIV?
The research landscape for curing HIV has changed substantially since 2007. That was the year when Timothy Ray ...
DECEMBER 13, 2019
New Studies Show Neural Tube Risk With Dolutegravir Lower Than Thought
WHO updated its global HIV treatment recommendations based on new data showing that even though dolutegravir during ...
JULY 24, 2019
Point-of-Care Testing Improves HIV Treatment Outcomes
Increased access to point of care testing could help the nearly half of all people living with HIV worldwide who ...
JULY 12, 2019
Biktarvy Demonstrates High Efficacy, Tolerability Through 96 Weeks
Gilead reported 96 week results for a comparative trial of Biktarvy in HIV patients who were treatment naive.
OCTOBER 9, 2018
